Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Redesigned Phase III Trial May Confirm Phase II Donanemab Results

Executive Summary

TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.

You may also be interested in...



Medicare Coverage For Alzheimer’s Drugs Could Align With Degree Of Plaque Removal, Lilly Says

Company maintains that the upcoming Medicare national coverage policy for Alzheimer’s drugs should not impose the same access restrictions on drugs with better evidence of effectiveness than others.

Lilly Is Revved Up About Alzheimer's Opportunity

The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody. 

Accelerated Approval Of Lilly’s Alzheimer’s Drug Could Last About 15 Months, CEO Says

Lilly expects results from donanemab ongoing confirmatory trial in 2023, while Biogen has nine years to finish its postmarket study. CEO David Ricks discusses impact of aducanumab approval backlash, pricing and national coverage decision at STAT summit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel